U.S. Gastrointestinal Therapeutics Market Size & Outlook
U.S. gastrointestinal therapeutics market, 2018-2030 (US$M)
Related Markets
U.S. gastrointestinal therapeutics market highlights
- The U.S. gastrointestinal therapeutics market generated a revenue of USD 12,271.0 million in 2022 and is expected to reach USD 14,690.1 million by 2030.
- The U.S. market is expected to grow at a CAGR of 2.3% from 2023 to 2030.
- In terms of segment, branded was the largest revenue generating drug type in 2022.
- Generics is the most lucrative drug type segment registering the fastest growth during the forecast period.
Gastrointestinal therapeutics market data book summary
| Market revenue in 2022 | USD 12,271.0 million |
| Market revenue in 2030 | USD 14,690.1 million |
| Growth rate | 2.3% (CAGR from 2022 to 2030) |
| Largest segment | Branded |
| Fastest growing segment | Generics |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Branded, Generics |
| Key market players worldwide | AbbVie Inc, AstraZeneca PLC, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Bayer AG, Abbott Laboratories, Janssen Pharmaceuticals, Sun Pharmaceutical Industries, Cipla Ltd DR, Gilead Sciences Inc, Biogen Inc, Organon & Co Ordinary Shares |
Other key industry trends
- In terms of revenue, U.S. accounted for 32.6% of the global gastrointestinal therapeutics market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. gastrointestinal therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 2,409.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Gastrointestinal Therapeutics Market Scope
Gastrointestinal Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. gastrointestinal therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastrointestinal therapeutics market will help companies and investors design strategic landscapes.
Branded was the largest segment with a revenue share of 69.51% in 2022. Horizon Databook has segmented the U.S. gastrointestinal therapeutics market based on branded, generics covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. accounted for the largest share in North America gastrointestinal therapeutics market and is anticipated to maintain its dominance during the forecast period, owing to high healthcare expenditure, rising prevalence of gastrointestinal disorders, and greater adoption of branded drugs.
Furthermore, key players in the market are extensively investing in R&D, which has resulted in numerous drug approvals in the recent years. For instance, in October 2019, Johnson & Johnson received FDA approval for its drug STELARA (ustekinumab) indicated for moderately to severely active ulcerative colitis in adult patients.
In addition, in June 2019, Allergan plc and its partner Ironwood Pharmaceuticals, Inc announced positive results from a phase IIIb clinical trial study investigating LINZESS (linaclotide) 290 mcg on multiple abdominal indications in adult patients with Irritable Bowel Syndrome with Constipation (IBS-C).
Reasons to subscribe to U.S. gastrointestinal therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. gastrointestinal therapeutics market databook
-
Our clientele includes a mix of gastrointestinal therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. gastrointestinal therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into U.S. gastrointestinal therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. gastrointestinal therapeutics market size, by drug type, 2018-2030 (US$M)
U.S. Gastrointestinal Therapeutics Market Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
